The pharmaceutical industry offers a structured and rewarding career path within Quality Assurance (QA), particularly for professionals aiming to progress towards becoming a Qualified Person (QP). This journey is not only about gaining experience but also about building technical knowledge, regulatory expertise, and leadership capability. If you're starting out as a QA Associate or
The pharmaceutical sector continues to expand across Ireland, the UK, Europe and global markets, with increased investment in biologics, advanced therapies, sterile manufacturing and digital transformation. As a result, demand for skilled Quality Assurance (QA) professionals remains strong. However, employers are becoming more selective. They are no longer hiring solely for experience or job
Biopharmaceutical manufacturing has undergone a significant transformation in recent years, driven by increasing regulatory expectations, complex production processes, and the need for greater efficiency. One of the most impactful developments supporting this evolution is the adoption of Digital Batch Records (DBRs), also commonly referred to as Electronic Batch Records (EBRs). Traditionally, pharmaceutical and biopharmaceutical
Advanced Therapy Medicinal Products (ATMPs) are rapidly transforming the pharmaceutical and biotechnology landscape. These therapies, which include gene therapies, cell therapies, and tissue-engineered products, offer groundbreaking treatments for conditions that previously had limited or no therapeutic options. As the number of ATMPs entering clinical development and commercial production continues to rise, regulatory authorities are
Cell and gene therapies (CGTs) represent one of the most transformative areas of modern medicine. These advanced therapies offer the potential to treat or even cure diseases that were previously considered untreatable, including certain cancers, genetic disorders, and rare diseases. However, the complexity of these therapies also presents unique manufacturing and quality challenges. Unlike
Quality by Design (QbD) has become a fundamental concept in modern pharmaceutical development and manufacturing. Rather than relying solely on end-product testing to ensure quality, QbD focuses on designing quality into products and processes from the earliest stages of development. First introduced by regulatory bodies such as the U.S. Food and Drug Administration (FDA)
Human error has long been recognised as one of the most common causes of quality deviations in manufacturing environments, particularly in highly regulated industries such as pharmaceuticals, biotechnology, and medical device production. While organisations invest heavily in systems, automation, and compliance frameworks, human factors continue to influence operational outcomes on the shop floor. In
In the pharmaceutical industry, quality has always been a regulatory requirement. However, in recent years, the conversation has shifted from simply meeting Good Manufacturing Practice (GMP) requirements to building a proactive quality culture embedded across the entire organisation. By 2025, many pharmaceutical leaders recognised that strong systems alone are not enough. Regulators, including the
In 2026, supply chains are more globalised, interconnected, and complex than ever before. Organisations increasingly rely on international suppliers to deliver raw materials, components, and services essential to their operations. While global sourcing provides cost advantages and access to specialised capabilities, it also introduces significant quality and compliance challenges. Supplier quality management has therefore
Remote auditing was once considered a temporary workaround and an emergency solution to maintain compliance during global disruption. But in 2026, it has cemented itself as a core component of modern quality oversight. The pharmaceutical and medical device industries, along with global regulatory authorities, have embraced hybrid audit models that blend on-site inspections with
